NPHC DD Small convertible left, around 45k, no new
Post# of 98045
(Total Views: 101)
Posted On: 04/17/2017 1:05:51 PM
NPHC DD Small convertible left, around 45k, no new converts until June and they hope to pay them off with cash. (18:45 mark)
In 2015 the pps was .27, they ran into problems trying to launch and distribute Nyloxin in India which lead to the current situation with converts. They took a lot of debt thinking big orders would come in.
They believe India is a big market for their pain products. He said traditional opioid pain meds aren't used there (cultural differences) and their biggest competition would be a topical aspirin. Also they are familiar with cobra venom and the product would make sense to them, where as in U.S. they may have to educate the market. India's middle class is almost 300 million strong (as big as total population of U.S.) They have over 2 million (retail value) in inventory so they are ready to sell both products.
He is excited about the PetPainAway launch with the infomercial. No similar pain products for pets on the market that don't just make them sleep or vomit/diarrhea. I recommend checking the commercial out, https://www.getpetpainaway.com/?mid=9068134.
Nyloxin lasts longer than morphine and is non addictive. Both products are very cheap to make, according to the NBC story 1 cobra "milking" makes more than 100 bottles. Here is the NBC story that features the products and the CEO, https://www.youtube.com/watch?v=sybsQsxMnqI There profit margin is higher than 80% according to this report, https://www.otcmarkets.com/financialReportVie...;id=169348
Lastly, they are trying to get their orphan drug RPI-78M to phase 2 this year. The pediatric MS market is 500 million a year and orphan status would give them marketing exclusivity for 7 years. The adult MS market is of course much bigger.
He said he thinks with the launch/relaunch of the pain products they can be cash flow positive this year. If they can do that, and get RPI-78M into phase 2 this looks pretty good.
In 2015 the pps was .27, they ran into problems trying to launch and distribute Nyloxin in India which lead to the current situation with converts. They took a lot of debt thinking big orders would come in.
They believe India is a big market for their pain products. He said traditional opioid pain meds aren't used there (cultural differences) and their biggest competition would be a topical aspirin. Also they are familiar with cobra venom and the product would make sense to them, where as in U.S. they may have to educate the market. India's middle class is almost 300 million strong (as big as total population of U.S.) They have over 2 million (retail value) in inventory so they are ready to sell both products.
He is excited about the PetPainAway launch with the infomercial. No similar pain products for pets on the market that don't just make them sleep or vomit/diarrhea. I recommend checking the commercial out, https://www.getpetpainaway.com/?mid=9068134.
Nyloxin lasts longer than morphine and is non addictive. Both products are very cheap to make, according to the NBC story 1 cobra "milking" makes more than 100 bottles. Here is the NBC story that features the products and the CEO, https://www.youtube.com/watch?v=sybsQsxMnqI There profit margin is higher than 80% according to this report, https://www.otcmarkets.com/financialReportVie...;id=169348
Lastly, they are trying to get their orphan drug RPI-78M to phase 2 this year. The pediatric MS market is 500 million a year and orphan status would give them marketing exclusivity for 7 years. The adult MS market is of course much bigger.
He said he thinks with the launch/relaunch of the pain products they can be cash flow positive this year. If they can do that, and get RPI-78M into phase 2 this looks pretty good.
(0)
(0)Scroll down for more posts ▼